You are here: Industry Insights > NMPA

News List

NMPA head pledges 'most rigorous administration' of vaccines at press conference chinadaily
July 23, 2019
The Eleventh Session of the Standing Committee of the 13th National People's Congress passed the Vaccine Administration Law of the People's Republic of China on June 29.
Overview of the Approval Trends of Pharmaceutical Products in the First Half of 2019 PharmaSources/Suyi
July 11, 2019
Clinically Imperative Overseas New Drugs Approved Accounting for a Larger Number
NMPA grants priority review to BeiGene's sNDA for tislelizumab biospectrumasia
July 08, 2019
The sNDA for tislelizumab as a potential treatment for patients with previously treated locally-advanced or metastatic UC was accepted by the NMPA in May 2019.
Different Clinical Layouts of Chinese-produced Products for Marching into the Anti-PD-1 Monoclonal Antibody Market PharmaSources/Xiaoyaowan
July 04, 2019
The marketing of camrelizumab means the beginning of the next stage of competition for layouts centering on multiple new indications.
NMPA accepts NDA for biosimilar product candidate of Rituximab biospectrumasia
June 28, 2019
IBI301 is a recombinant human-mouse chimeric anti-cell surface protein (anti-CD20) monoclonal antibody for injection co-developed by Lilly and Innovent for the treatment of non-Hodgkin's lymphoma (NHL) and other diseases.
Henlius biosimilar HLX02 gets NDA acceptance from NMPA biospectrumasia
May 09, 2019
HLX02 is a biosimilar developed by Henlius with independent intellectual property for the treatment of HER2 positive metastatic breastcancer (BC) and metastatic gastric cancer (GC)
China National Medical Products Administration Approves Sinovant's Clinical Trial Application for Derazantinib prnewswire
April 29, 2019
Sinovant Sciences today announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA)
China’s NMPA approves Novartis’ Cosentyx and Merck’s Keytruda pharmaceutical-technology
April 23, 2019
Novartis has announced that the Chinese National Medical Product Administration (NMPA) has approved its plaque psoriasis drug Cosentyx (secukinumab).
Global Innovative Drugs Speeding up to Enter China with the Help from Policies PharmaSources/1℃
April 17, 2019
The National Medical Products Administration (NMPA) and National Health Commission of China organized relevant experts on Mar. 28, 2019 to...
NMPA approves Novartis's Cosentyx for psoriasis patients biospectrumasia
April 03, 2019
Cosentyx is the first biologic approved in China that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page